BTX
Brooklyn ImmunoTherapeutics, Inc. [BTX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BTX Stock Summary
In the News
BTX Financial details
Company Rating
-
Market Cap
1.05M
Income
-21.67M
Revenue
68K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
09 Nov 2022
P/E
-0.47
Forward P/E
-
PEG
0.1
P/S
-
P/B
0.79
P/C
-
P/FCF
-0.46
Quick Ratio
1.5
Current Ratio
1.79
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.08
EPS next Y
-
EPS next Q
-
EPS this Y
-49.38%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-32.2%
Revenue last 5Y
-67.85%
Revenue Q/Q
-66.67%
EPS Q/Q
10.68%
-
-
-
-
SMA20
-13.81%
SMA50
17.42%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-92%
ROE
-155%
ROC
-1.41%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.181-200.0
52W High
-
52W Low
-
RSI
38.12
Rel Volume
0.24
Avg Volume
85.43K
Volume
20.64K
Perf Week
-21.85%
Perf Month
13.44%
Perf Quarter
-
Perf Half Y
20.26%
-
-
-
-
Beta
0.78748
-
-
Volatility
0.27%, 0.48%
Prev Close
-1.3%
Price
3.8001
Change
-9.09%
Company Profile
- Volume Average 85.43K
- Market Capitalization 1.05M
- Employee 10
- CEO Mr. Allen Wolff
- Headquarters Carlsbad,CALIFORNIA,US
- IPO Date 1991-08-29
-
Website
https://www.brooklynitx.com 
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
